HHS Action On Drug Pricing: Here's Who Secretary Price Is Listening To
Executive Summary
HHS is expected to move ahead with action to address high drug prices following a series of stakeholder roundtables held over the past month.
You may also be interested in...
HHS Leadership Upheaval Could Delay Initiatives Impacting Biopharma
Secretary Price will be succeeded on an acting basis by HHS acting assistant secretary for health Donald Wright, and everything from development of the executive order on drug pricing to pending Medicare reimbursement experiments could see a pause as part of the transition.
Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
340B Program Controls: House Committee Launches Investigation
Energy and Commerce Committee leadership requests audit records and other documents from the Health Resources and Services Administration to evaluate the effectiveness of its oversight of the program.